Skip to main
COGT
COGT logo

Cogint (COGT) Stock Forecast & Price Target

Cogint (COGT) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 38%
Buy 38%
Hold 23%
Sell 0%
Strong Sell 0%

Bulls say

Cogent Biosciences, Inc. is projected to experience significant sales growth, with estimates reaching approximately $225 million in 2032, reflecting a 60% probability of success for its lead programs. The company’s CGT9486 program has demonstrated favorable outcomes in initial trials compared to historical controls, indicating strong potential in treating Systemic Mastocytosis and advanced gastrointestinal stromal tumors. Additionally, the competitive profile of Bezuclastinib against existing therapies suggests the possibility of capturing meaningful market share, further enhancing the company's financial outlook.

Bears say

The financial outlook for Cogent Biosciences Inc is negatively impacted by several key risks, including the potential for unfavorable clinical data, slower-than-expected timelines in clinical development, and the possibility of setbacks in regulatory approvals. Notably, there are concerns regarding the safety profile of bezuclastinib in non-advanced systemic mastocytosis, which could hinder its market adoption despite its efficacy. Furthermore, projections for commercial success have been adjusted downward, as indicated by a significant revision in peak market penetration estimates for its therapies from 50% to 20%, reflecting increased competition and a more cautious market landscape.

Cogint (COGT) has been analyzed by 13 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 38% recommend Buy, 23% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cogint and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cogint (COGT) Forecast

Analysts have given Cogint (COGT) a Buy based on their latest research and market trends.

According to 13 analysts, Cogint (COGT) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cogint (COGT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.